NEW YORK CITY, NY / ACCESS Newswire / October 30, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akebia Therapeutics, Inc. ("Akebia" or "the Company") (NASDAQ:AKBA). Investors who purchased Akebia securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/AKBA.
Investigation Details
On October 28, 2025, Akebia issued a press release "announc[ing] that after meeting with the U.S. Food and Drug Administration (FDA) it has not come to alignment on a path forward for the design of the VALOR clinical trial for the use of vadadustat to treat anemia in patients with late-stage chronic kidney disease (CKD) not on dialysis. As a result, Akebia does not plan to initiate VALOR and therefore does not expect to pursue a broad label for Vafseo for CKD non-dialysis dependent patients." Following this news, Akebia’s stock price fell $0.99 per share, or 32.04%, to close at $2.10 on October 29, 2025.
What’s Next?
If you are aware of any facts relating to this investigation or purchased Akebia securities, you can assist this investigation by visiting the firm’s site: bgandg.com/AKBA. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | info@bgandg.com
SOURCE: Bronstein, Gewirtz & Grossman, LLC
View the original press release on ACCESS Newswire
COMTEX_469913220/2457/2025-10-30T11:52:18